AbbVie Inc.'s combination therapy for hepatitis C, Maviret (glecaprevir/pibrentasvir), has been recommended for non-prescription use under certain conditions by New Zealand’s Medicines Classification Committee (MCC).
At its most recent meeting on 25 May, the MCC expanded the dispensing conditions for glecaprevir (100mg) in combination with pibrentasvir (40mg) to include pharmacists who meet the requirements of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?